XORTX Therapeutics (XRTX) Net Income (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Net Income came in at -$808472.0 in Q1 2026, down 15.72% YoY from -$959216.3 in Q1 2025, and down 36.92% on a QoQ basis from -$590462.0 in Q4 2025.
XORTX Therapeutics (XRTX) Net Income (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Net Income data on file, last reported at -$808472.0 in Q1 2026.
- Quarterly Net Income fell 15.72% year-over-year to -$808472.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (down 149.1% YoY) and the FY2025 annual result came in at -$2.7 million, down 180.17% from the prior year.
- Net Income retreated to -$808472.0 in Q1 2026, from -$590462.0 in the prior quarter.
- In the past five years, Net Income ranged from a high of $6.7 million in Q4 2024 to a low of -$3.0 million in Q1 2024.
- A 5-year average of -$702251.9 and a median of -$808472.0 in 2026 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income plunged 597.94% — and 2024, when it jumped 113.5%.
- Tracing XRTX's Net Income over 5 years: stood at -$2.1 million in 2022, then jumped by 41.41% to -$1.3 million in 2023, then soared by 635.85% to $6.7 million in 2024, then sank by 108.75% to -$590462.0 in 2025, then tumbled by 36.92% to -$808472.0 in 2026.
- The last three Net Income figures came in at -$808472.0 (Q1 2026), -$590462.0 (Q4 2025), and -$649469.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | XORTX Therapeutics | 2.78 Mn | 2.78 Mn | - | -808,472.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -808,472.00 |
| Dec 31, 2025 | -590,462.00 |
| Sep 30, 2025 | -649,469.00 |
| Jun 30, 2025 | -717,700.00 |
| Mar 31, 2025 | -698,673.00 |
| Dec 31, 2024 | 6.75 Mn |
| Sep 30, 2024 | -587,011.00 |
| Jun 30, 2024 | 170,066.00 |
| Mar 31, 2024 | -3.02 Mn |
| Jun 30, 2023 | -1.26 Mn |
| Mar 31, 2023 | -1.83 Mn |
| Dec 31, 2022 | -2.15 Mn |
| Sep 30, 2022 | -1.20 Mn |
| Jun 30, 2022 | -1.24 Mn |
| Mar 31, 2022 | -2.70 Mn |
| Dec 31, 2021 | 9.84 Mn |
| Sep 30, 2021 | -6.64 Mn |
| Jun 30, 2021 | -177,711.75 |
| Mar 31, 2021 | -1.72 Mn |
| Dec 31, 2020 | 1.62 Mn |